Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM GA 68 EDOTREOTIDE versus INDIUM IN 111 CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM GA 68 EDOTREOTIDE versus INDIUM IN 111 CHLORIDE.
GALLIUM GA 68 EDOTREOTIDE vs INDIUM IN 111 CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium Ga 68 edotreotide is a radiopharmaceutical analog of somatostatin that binds to somatostatin receptors, particularly subtype 2 (SSTR2), which are overexpressed on neuroendocrine tumor cells. After binding, internalization occurs, and the gallium-68 isotope emits positrons for PET imaging.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
148-259 MBq (4-7 mCi) IV once for PET imaging.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
None Documented
None Documented
Terminal elimination half-life: 0.5–2.5 hours (mean 1.2 hours); clinically allows same-day imaging after injection.
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Renal: >90% unchanged in urine within 24 hours; biliary/fecal: <2%.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical